Clinical Trial Update: Open-Label Treatment Extension of Protocol MNTX 302 [Phase 3]

View source ↗

Summary

Open-label treatment extension update for a Phase 3 trial (MNTX 302) sponsored by Bausch Health Americas, completed, in terminal illness.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Terminal Illness

Drugs mentioned

• MNTX 302

Snippet

Sponsor: Bausch Health Americas, Inc. | Conditions: Terminal Illness | Phase 3 | Status: COMPLETED